Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03509012
Title Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

lung small cell carcinoma

head and neck squamous cell carcinoma

lung non-small cell carcinoma

Therapies

Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab

Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium

Cisplatin + Durvalumab + Etoposide

Cisplatin + Durvalumab

Carboplatin + Durvalumab + Paclitaxel

Carboplatin + Cisplatin + Durvalumab + Etoposide

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.